Journal article
Experimental treatment of Ebola virus disease with TKM-130803: a single-arm phase 2 clinical trial
- Abstract:
- TKM-130803, a small interfering RNA lipid nanoparticle product, has been developed for the treatment of Ebola virus disease (EVD), but its efficacy and safety in humans has not been evaluated.In this single-arm phase 2 trial, adults with laboratory-confirmed EVD received 0.3 mg/kg of TKM-130803 by intravenous infusion once daily for up to 7 d. On days when trial enrolment capacity was reached, patients were enrolled into a concurrent observational cohort. The primary outcome was survival to day 14 after admission, excluding patients who died within 48 h of admission. After 14 adults with EVD had received TKM-130803, the pre-specified futility boundary was reached, indicating a probability of survival to day 14 of ≤0.55, and enrolment was stopped. Pre-treatment geometric mean Ebola virus load in the 14 TKM-130803 recipients was 2.24 × 109 RNA copies/ml plasma (95% CI 7.52 × 108, 6.66 × 109). Two of the TKM-130803 recipients died within 48 h of admission and were therefore excluded from the primary outcome analysis. Of the remaining 12 TKM-130803 recipients, nine died and three survived. The probability that a TKM-130803 recipient who survived for 48 h will subsequently survive to day 14 was estimated to be 0.27 (95% CI 0.06, 0.58). TKM-130803 infusions were well tolerated, with 56 doses administered and only one possible infusion-related reaction observed. Three patients were enrolled in the observational cohort, of whom two died.Administration of TKM-130803 at a dose of 0.3 mg/kg/d by intravenous infusion to adult patients with severe EVD was not shown to improve survival when compared to historic controls.Pan African Clinical Trials Registry PACTR201501000997429.
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Version of record, pdf, 1.0MB, Terms of use)
-
- Publisher copy:
- 10.1371/journal.pmed.1001997
Authors
- Publisher:
- Public Library of Science
- Journal:
- PLoS Medicine More from this journal
- Volume:
- 13
- Issue:
- 4
- Pages:
- e1001997
- Publication date:
- 2016-04-19
- Acceptance date:
- 2016-03-08
- DOI:
- EISSN:
-
1549-1676
- ISSN:
-
1549-1277
- Language:
-
English
- Keywords:
- Pubs id:
-
pubs:616748
- UUID:
-
uuid:cf33dd63-85ea-4762-8ebf-e412d406523d
- Local pid:
-
pubs:616748
- Source identifiers:
-
616748
- Deposit date:
-
2016-05-17
- ARK identifier:
Terms of use
- Copyright holder:
- Jake Dunning et al
- Copyright date:
- 2016
- Notes:
- This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
- Licence:
- CC Attribution (CC BY)
If you are the owner of this record, you can report an update to it here: Report update to this record